// App-Quantinova.ai

: A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer.

Researchers

Presenter

  • Cayce Ben Nawaf

Principal Investigators

  • Bo Peng

  • Melissa Andrea Reimers

  • Cody Weimholt

  • Kathryn Slane

  • Peter John Oppelt

  • Jason Frankel

  • Robert S. Figenshau

  • Eric H Kim

  • Gerald L. Andriole

  • Lawrence Fong

  • Russell Kent Pachynski

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • University of California, San Francisco, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Bruton tyrosine kinase

  • Breakpoint Cluster Region

  • Programmed death-ligand 1

  • T-cell receptor

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02643667

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved